Patents by Inventor Stuart A. Lipton

Stuart A. Lipton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11529319
    Abstract: Disclosed herein are methods for treating juvenile onset neurological conditions, such as autism (ASD), intellectual disability, or epilepsy, with an inhibitor of N-methyl-D-aspartate receptor (NMDAR). The inhibitor may be NitroSynapsin or a derivative thereof.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: December 20, 2022
    Inventor: Stuart A. Lipton
  • Publication number: 20200368177
    Abstract: Disclosed herein are methods for treating juvenile onset neurological conditions, such as autism (ASD), intellectual disability, or epilepsy, with an inhibitor of N-methyl-D-aspartate receptor (NMDAR). The inhibitor may be NitroSynapsin or a derivative thereof.
    Type: Application
    Filed: July 31, 2018
    Publication date: November 26, 2020
    Inventor: Stuart A. LIPTON
  • Patent number: 8466311
    Abstract: Neurite outgrowth-promoting prostaglandins (NEPPs) and other electrophilic compounds bind to Keap1, a negative regulator of the transcription factor Nrf2, and prevent Keap1-mediated inactivation of Nrf2 and, thus, enhance Nrf2 translocation into the nucleus of neuronal cells. Therefore, neuroprotective compositions and related methods are provided that employ such neuroprotective compounds, and prodrugs of such compounds, to cause dissociation of Nrf2 from a Keap1/Nrf2 complex.
    Type: Grant
    Filed: September 19, 2011
    Date of Patent: June 18, 2013
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Stuart A. Lipton, Takumi Satoh
  • Publication number: 20120296112
    Abstract: Neurite outgrowth-promoting prostaglandins (NEPPs) and other electrophilic compounds bind to Keap1, a negative regulator of the transcription factor Nrf2, and prevent Keap1-mediated inactivation of Nrf2 and, thus, enhance Nrf2 translocation into the nucleus of neuronal cells. Therefore, neuroprotective compositions and related methods are provided that employ such neuroprotective compounds, and prodrugs of such compounds, to cause dissociation of Nrf2 from a Keap1/Nrf2 complex.
    Type: Application
    Filed: September 19, 2011
    Publication date: November 22, 2012
    Inventors: Stuart A. Lipton, Takumi Satoh
  • Patent number: 8236563
    Abstract: The present invention provides a method of differentiating progenitor cells to produce a population containing protected neuronal cells. A method of the invention includes the steps of contacting the progenitor cells with a differentiating agent; and introducing into the progenitor cells a nucleic acid molecule encoding a MEF2 polypeptide or an active fragment thereof, thereby differentiating the progenitor cells to produce a population containing protected neuronal cells. In one embodiment, the MEF2 polypeptide is human MEF2C or an active fragment thereof.
    Type: Grant
    Filed: March 31, 2011
    Date of Patent: August 7, 2012
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Stuart A Lipton, Shu-ichi Okamoto
  • Patent number: 8193315
    Abstract: The invention provides isolated N-methyl-D-aspartate type 3B (NR3B) polypeptides, functional fragments and peptides, encoding nucleic acid molecules and polynucleotides, and specific antibodies. Also provided are excitatory glycine receptors, containing either NR3B or NR3A polypeptides. Further provided are methods for detecting excitatory glycine receptor ligands, agonists and antagonists. The invention also provides related diagnostic and therapeutic methods.
    Type: Grant
    Filed: July 23, 2010
    Date of Patent: June 5, 2012
    Assignees: Sanford-Burnham Medical Research Institute, Yale University, The Brigham and Women's Hospital, Inc.
    Inventors: Stuart A. Lipton, Dongxian Zhang, Jon E. Chatterton, Kevin A. Sevarino, Marc Awobuluyi
  • Publication number: 20110293556
    Abstract: This invention relates to Applicant's discovery that Metabolic Syndrome , a cluster of disorders stemming from a resistance to insulin, contributes directly to dementia, particularly Alzheimer's disease. Applicant's invention includes a screening method to determine susceptibility and diagnosis of dementia based on the risk factors for Metabolic Syndrome. Applicant's invention further includes methods for the prevention or treatment of dementia and other neurological conditions based on (1) minimizing insulin resistance, thereby preventing excess biosynthesis of insulin; (2) modulating the activity of IDE such that insulin competes less efficiently with ?-amyloid protein for the TDE; and (3) blocking the consequences of NMDA receptor activation, such as by minimizing the generation of NO and other harmful free radicals.
    Type: Application
    Filed: August 8, 2011
    Publication date: December 1, 2011
    Applicant: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
    Inventors: Stuart A. LIPTON, Daniel EINHORN
  • Patent number: 8022246
    Abstract: Neurite outgrowth-promoting prostaglandins (NEPPs) and other electrophilic compounds bind to Keap1, a negative regulator of the transcription factor Nrf2, and prevent Keap1-mediated inactivation of Nrf2 and, thus, enhance Nrf2 translocation into the nucleus of neuronal cells. Therefore, neuroprotective compositions and related methods are provided that employ such neuroprotective compounds, and prodrugs of such compounds, to cause dissociation of Nrf2 from a Keap1/Nrf2 complex.
    Type: Grant
    Filed: October 10, 2007
    Date of Patent: September 20, 2011
    Assignee: The Burnham Institute for Medical Research
    Inventors: Stuart Lipton, Takumi Satoh
  • Publication number: 20110212070
    Abstract: The present invention provides a method of differentiating progenitor cells to produce a population containing protected neuronal cells. A method of the invention includes the steps of contacting the progenitor cells with a differentiating agent; and introducing into the progenitor cells a nucleic acid molecule encoding a MEF2 polypeptide or an active fragment thereof, thereby differentiating the progenitor cells to produce a population containing protected neuronal cells. In one embodiment, the MEF2 polypeptide is human MEF2C or an active fragment thereof.
    Type: Application
    Filed: March 31, 2011
    Publication date: September 1, 2011
    Applicant: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
    Inventors: Stuart A. Lipton, Shu-ichi Okamoto
  • Publication number: 20110171291
    Abstract: Disclosed are methods and compositions for identifying, producing, and using pathologically-activated targeting compounds. Pathologically-activated compounds are compound that only have an effect, or have a disproportionate effect, on a target molecule when a pathological condition exists.
    Type: Application
    Filed: January 7, 2011
    Publication date: July 14, 2011
    Inventor: Stuart A. Lipton
  • Publication number: 20110091568
    Abstract: Compositions for application to the skin of individuals in need thereof are provided that include media conditioned by the growth of human stem cells, particularly human neural stem cells. In some embodiments, the stem cells are grown without the use of feeder layers.
    Type: Application
    Filed: April 7, 2010
    Publication date: April 21, 2011
    Inventors: Stuart A. Lipton, Alexey Terskikh
  • Patent number: 7919317
    Abstract: The present invention provides a method of differentiating progenitor cells to produce a population containing protected neuronal cells. A method of the invention includes the steps of contacting the progenitor cells with a differentiating agent; and introducing into the progenitor cells a nucleic acid molecule encoding a MEF2 polypeptide or an active fragment thereof, thereby differentiating the progenitor cells to produce a population containing protected neuronal cells. In one embodiment, the MEF2 polypeptide is human MEF2C or an active fragment thereof.
    Type: Grant
    Filed: June 5, 2001
    Date of Patent: April 5, 2011
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Stuart A. Lipton, Shu-ichi Okamoto
  • Publication number: 20110045098
    Abstract: The invention provides isolated N-methyl-D-aspartate type 3B (NR3B) polypeptides, functional fragments and peptides, encoding nucleic acid molecules and polynucleotides, and specific antibodies. Also provided are excitatory glycine receptors, containing either NR3B or NR3A polypeptides. Further provided are methods for detecting excitatory glycine receptor ligands, agonists and antagonists. The invention also provides related diagnostic and therapeutic methods.
    Type: Application
    Filed: July 23, 2010
    Publication date: February 24, 2011
    Applicants: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE, THE BRIGHAM AND WOMEN'S HOSPITAL, INC., YALE UNIVERSITY
    Inventors: STUART A. LIPTON, DONGXIAN ZHANG, JON E. CHATTERTON, KEVIN A. SEVARINO, MARC AWOBULUYI
  • Patent number: 7790404
    Abstract: The invention provides isolated N-methyl-D-aspartate type 3B (NR3B) polypeptides, functional fragments and peptides, encoding nucleic acid molecules and polynucleotides, and specific antibodies. Also provided are excitatory glycine receptors, containing either NR3B or NR3A polypeptides. Further provided are methods for detecting excitatory glycine receptor ligands, agonists and antagonists. The invention also provides related diagnostic and therapeutic methods.
    Type: Grant
    Filed: August 16, 2002
    Date of Patent: September 7, 2010
    Assignees: Sanford-Burnham Medical Research Institute, Yale University, The Brigham and Women's Hospital, Inc.
    Inventors: Stuart A. Lipton, Dongxian Zhang, Jon E. Chatterton, Kevin A Sevarino, Marc Awobuluyi
  • Publication number: 20100137448
    Abstract: The present invention relates to compositions and methods for treating a human patient afflicted with a neuropsychiatric disorder. Specifically, the invention provides for compositions and methods of modulating or antagonizing the activity of neuronal NMDA receptors, wherein such antagonistic activity is capable of modulating the glutamate induced excitatory response of the neurons, thereby inhibiting an excitotoxic effect, promoting a neurotrophic effect, and thereby providing a therapeutic effect that treats the neuropsychiatric disorder.
    Type: Application
    Filed: July 16, 2009
    Publication date: June 3, 2010
    Inventors: Stuart A. Lipton, Gregory Went
  • Publication number: 20090234021
    Abstract: The present invention provides novel methods and compositions for the treatment of multiple sclerosis.
    Type: Application
    Filed: October 6, 2008
    Publication date: September 17, 2009
    Inventors: Stuart A. Lipton, Gregory T. Went, Laurence R. Meyerson
  • Publication number: 20090209615
    Abstract: The invention provides methods to treat neurological disorders, opthalmological disorders, or a combination thereof by administering a compound that inhibits MMPs. A compound that inhibits MMPs is represented by the compound of formula (I) shown herein.
    Type: Application
    Filed: September 27, 2005
    Publication date: August 20, 2009
    Inventors: Stuart Lipton, Alex Strongin, Shahriar Mobashery, Zezong Gu
  • Publication number: 20090093409
    Abstract: The present invention provides a method of providing acute neuroprotection by inducing the erythropoietin (EPO) signaling pathway in neuronal cells close to or subsequent to the time of excitatory insult; and inducing an insulin-like growth factor (IGF) signaling pathway in the neuronal cells close to or subsequent to the time of excitatory insult, thereby producing a synergistic acute neuroprotective effect in the neuronal cells. The invention also provides a method of preventing or reducing the severity of a neurologic condition in a subject by administering to the subject EPO or an active fragment or analog thereof at a dose of at most 2000 U/kg; and administering to the subject an IGF or an active fragment or analog thereof, thereby providing neuroprotection and preventing or reducing the severity of the neurologic condition.
    Type: Application
    Filed: October 15, 2008
    Publication date: April 9, 2009
    Applicant: Burnham Institute for Medical Research
    Inventors: Murat Digicaylioglu, Stuart A. Lipton
  • Publication number: 20090088367
    Abstract: This invention relates to Applicant's discovery that Metabolic Syndrome, a cluster of disorders stemming from a resistance to insulin, contributes directly to dementia, particularly Alzheimer's disease. Applicant's invention includes a screening method to determine susceptibility and diagnosis of dementia based on the risk factors for Metabolic Syndrome. Applicant's invention further includes methods for the prevention or treatment of dementia and other neurological conditions based on (1) minimizing insulin resistance, thereby preventing excess biosynthesis of insulin; (2) modulating the activity of IDE such that insulin competes less efficiently with ?-amyloid protein for the IDE; and (3) blocking the consequences of NMDA receptor activation, such as by minimizing the generation of NO and other harmful free radicals.
    Type: Application
    Filed: May 10, 2005
    Publication date: April 2, 2009
    Applicant: Burnham Institute For Medical Research
    Inventors: Stuart A. Lipton, Daniel Einhorn
  • Publication number: 20090042980
    Abstract: Neurite outgrowth-promoting prostaglandins (NEPPs) and other electrophilic compounds bind to Keap1, a negative regulator of the transcription factor Nrf2, and prevent Keap1-mediated inactivation of Nrf2 and, thus, enhance Nrf2 translocation into the nucleus of neuronal cells. Therefore, neuroprotective compositions and related methods are provided that employ such neuroprotective compounds, and prodrugs of such compounds, to cause dissociation of Nrf2 from a Keap1/Nrf2 complex.
    Type: Application
    Filed: October 10, 2007
    Publication date: February 12, 2009
    Applicant: Burnham Institute for Medical Research
    Inventors: Stuart A. Lipton, Takumi Satoh